Drug Profile


Alternative Names: 2-fluorofucose peracetate; 2FF; SGD-2083; SGN-2FF

Latest Information Update: 22 Feb 2017

Price : $50

At a glance

  • Originator Seattle Genetics
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Carbohydrate metabolism inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Cancer
  • Preclinical Sickle cell anaemia

Most Recent Events

  • 01 Feb 2017 Phase-I clinical trials in Cancer (Late-stage disease, Refractory metastatic disease, Second-line therapy or greater) in USA (PO)
  • 31 Oct 2016 Seattle Genetics plans a phase I trial for Cancer (Second-line therapy or greater, Late-stage disease, Metastatic disease) in USA (PO) (NCT02952989)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top